Updated on 21 August 2015
The company plans to invest $70.87 million for the construction that will be completed in 2 years
Singapore: Indonesia's Kimia Farma announced plans to invest Rp978 billion ($70.87 million) in a new pharmaceutical manufacturing facility dedicated for the manufacturing of herbal medicines, at Banjaran Industrial Estate, Bandung, West Java. The construction for the new plant is expected to begin in the current year and it is scheduled to be completed within two years.
Mr Rusdi Rosman, president director, Kimia Farma, said in a statement that the new plant was designed to have a production capacity of around 3.6 billion tablets per year, which is more than triple the existing capacity of 1.1 billion tablets.
The plant would soon become one of Indonesia's largest herbal medicines factory that conducts the synthesis, extraction and production of the raw herbal ingredients. The company is also eyeing overseas markets for its herbal medicine products, he added.
Mr Rosman also mentioned that the company will cooperate with a South Korean partner to build a factory in Lippo Cikarang Industrial Estate in Bekasi, West Java to produce raw materials for medicines. Kimia Farma mentioned that these attempts will help in reducing imports of raw materials for the medicines. The project is expected to kick off by the end of this year.